Developing A Diversified Pipeline That Targets Resilient Cancers.
Developing A Diversified Pipeline That Targets Resilient Cancers.
Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as therapeutic agents ENV105 and ENV205 for drug resistance.
Industry leading team with a strong track record of drug development, commercialization and multiple M&A exits.
Uniquely positioned to advance our novel drug development pipeline of peptide and small molecule cancer immunotherapeutics: KROS-101, 102, 201, 301, and 401 as well as therapeutic agents ENV105 and ENV205 for drug resistance
Industry leading team with a strong track record of drug development, commercialization and multiple M&A exits.
Proprietary technologies were licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. providing infrastructure and support to further advance development.
Multi-year plan in place for Phase II ENV105 prostate cancer trial, Phase I ENV105 for non-small cell lung cancer trial, and Phase I KROS-201 glioblastoma clinical trial.
Proprietary technologies were licensed from Cedars-Sinai Medical Center, the largest academic medical center in the Western U.S. providing infrastructure and support to further advance development.
Multi-year plan in place for Phase II ENV105 prostate cancer trial, Phase I ENV105 for non-small cell lung cancer trial, and Phase I KROS-201 glioblastoma clinical trial.
Disciplined focus on IP, exclusive world-wide patent licenses.
High value market - targeting a fast growing $311 Billion drug industry.
Disciplined focus on IP, exclusive world-wide patent licenses.
High value market - targeting a fast growing $311 Billion drug industry.
WHY KAIROS?
|
Unmet Medical Need |
Drug |
How Kairos Addresses Unmet Medical Need |
|
Resistance to hormone and EGFR therapies for multiple cancer types develop through the upregulation of CD105 signaling |
ENV 105 |
•Aims to target CD105 signaling to reverse cancer drug resistance |
|
Immunosuppression from cancer |
KROS 201 |
•Aims to generate killer T cells outside of immunosuppressed body |
|
T cells diminished by cancer Autoimmune T cells are overactive |
KROS 101 KROS 102 |
•Aims to expand killer T cells and inhibits suppressor T reg cells •Aims to diminish overactive T cells and increases Treg suppressor cells |
|
Chemotherapies are immunosuppressive |
KROS 301 |
•By exploiting the NF-kB molecular pathway in dependent cancers, KROS 301 aims to kill tumors and inhibit the mechanism of PD-L1 expression on tumor cells |
|
Tumor environment is immunosuppressive from macrophages |
KROS 401 |
•Aims to transform immunosuppressive macrophages to tumor killing macrophages |
|
Chemotherapy stops working as cancers become resistant; Cancer patients become cachexic |
ENV 205 |
•Aims to support chemotherapy sensitivity by reversing resistance •Aims to limit debilitating muscle wasting disease (cachexia) common to patients with cancer |
WHY KAIROS?
|
Unmet Medical Need |
Drug |
How Kairos Addresses Unmet Medical Need |
|
Resistance to hormone and EGFR therapies for multiple cancer types develop through the upregulation of CD105 signaling |
ENV 105 |
•Aims to target CD105 signaling to reverse cancer drug resistance |
|
Immunosuppression from cancer |
KROS 201 |
•Aims to generate killer T cells outside of immunosuppressed body |
|
T cells diminished by cancer Autoimmune T cells are overactive |
KROS 101 KROS 102 |
•Aims to expand killer T cells and inhibits suppressor T reg cells •Aims to diminish overactive T cells and increases Treg suppressor cells |
|
Chemotherapies are immunosuppressive |
KROS 301 |
•By exploiting the NF-kB molecular pathway in dependent cancers, KROS 301 aims to kill tumors and inhibit the mechanism of PD-L1 expression on tumor cells |
|
Tumor environment is immunosuppressive from macrophages |
KROS 401 |
•Aims to transform immunosuppressive macrophages to tumor killing macrophages |
|
Chemotherapy stops working as cancers become resistant; Cancer patients become cachexic |
ENV 205 |
•Aims to support chemotherapy sensitivity by reversing resistance •Aims to limit debilitating muscle wasting disease (cachexia) common to patients with cancer |
OUR MISSION
Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.
By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.
OUR MISSION
Kairos Pharma is a clinical stage biopharmaceutical company that harnesses immunity against cancer and drug resistance.
By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.
